Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASENSUS SURGICAL, INC.ASXC · Entity 88098 | Director | June 30, 2021 | July 02, 2021 |
| Cocrystal Pharma, Inc.COCP · Entity 7621 | Director | September 21, 2018 | September 24, 2018 |
| NON INVASIVE MONITORING SYSTEMS INC /FL/NIMU · Entity 7976 | Director · Interim CEO · 10% owner | December 21, 2018 | December 28, 2018 |
| OPKO HEALTH, INC.OPK · Entity 4891 | Director · Vice Chairman & CTO | May 27, 2025 | May 29, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASENSUS SURGICAL, INC.
Report date June 30, 2021 · Filed July 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 336,895 |
Reported balance
After 2021-07-01 transaction · row 1
1 source rowRow 1 · 2021-07-01 · Grant · Acquired 29,231 · Balance 336,895 F1: Represents restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Registrant's common stock. F2: Forfeiture restrictions will lapse on the RSUs on the first anniversary of the date of grant, provided that if the date of the 2022 annual meeting of stockholders is earlier, the restrictions will lapse on the date of the annual meeting. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.17 · Expires 2028-06-30 | Direct | 3,748 |
Reported balance
After 2021-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-06-30 · Grant · Acquired 3,748 · Balance 3,748 F4: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan in lieu of an annual cash retainer, paid quarterly in arrears for the quarter ended June 30, 2021. F5: The award is fully exercisable six months after the grant date, subject to earlier acceleration as approved by the Board of Directors. |
| Common StockSEC Table I · non-derivative | IndirectHsu Gamma Investments, L.P. | 96,746 |
Reported balance
Holding disclosure · report date 2021-06-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 96,746 F3: The Reporting Person is the general partner of Hsu Gama Investments, LP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Registrant's common stock.
F2: Forfeiture restrictions will lapse on the RSUs on the first anniversary of the date of grant, provided that if the date of the 2022 annual meeting of stockholders is earlier, the restrictions will lapse on the date of the annual meeting.
F3: The Reporting Person is the general partner of Hsu Gama Investments, LP.
F4: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan in lieu of an annual cash retainer, paid quarterly in arrears for the quarter ended June 30, 2021.
F5: The award is fully exercisable six months after the grant date, subject to earlier acceleration as approved by the Board of Directors.
Cocrystal Pharma, Inc.
Report date September 21, 2018 · Filed September 24, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.78 · Expires 2028-09-20 | Direct | 50,000 |
Reported balance
After 2018-09-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-09-21 · Grant · Acquired 50,000 · Balance 50,000 F1: The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments.
NON INVASIVE MONITORING SYSTEMS INC /FL/
Report date December 21, 2018 · Filed December 28, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par value per shareSEC Table I · non-derivative | Direct | 16,752,074 |
Ending reported balance
After 2018-12-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-12-21 · Purchase · Acquired 1,428,571 · Balance 11,828,571 Row 2 · 2018-12-21 · Purchase · Acquired 4,923,503 · Balance 16,752,074 F1: Shares acquired in exchange for indebtedness owed by Non-Invasive Monitoring Systems, Inc. to the reporting person or affiliates thereof. |
| Common Stock, $0.01 par value per shareSEC Table I · non-derivative | IndirectSee Footnote | 20,883,660 |
Reported balance
After 2018-12-21 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2018-12-21 · Purchase · Acquired 20,883,660 · Balance 20,883,660 F1: Shares acquired in exchange for indebtedness owed by Non-Invasive Monitoring Systems, Inc. to the reporting person or affiliates thereof. F2: Held by Hsu Gamma Investments LP, of which the reporting person is the general partner. The reporting person disclaims beneficial ownership of all shares held by Hsu Gamma Investments, LP except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired in exchange for indebtedness owed by Non-Invasive Monitoring Systems, Inc. to the reporting person or affiliates thereof.
F2: Held by Hsu Gamma Investments LP, of which the reporting person is the general partner. The reporting person disclaims beneficial ownership of all shares held by Hsu Gamma Investments, LP except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
OPKO HEALTH, INC.
Report date May 27, 2025 · Filed May 29, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31 · Expires 2035-05-26 | Direct | 500,000 |
Reported balance
After 2025-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-27 · Grant · Acquired 500,000 · Balance 500,000 F1: This option will vest in four equal annual installments beginning May 27, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest in four equal annual installments beginning May 27, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2017 Filed May 11, 2017 10:50 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 2,600 | $6.95 | $18,070.00 |
DisclosureSEC source: 0001209191-17-031425 · doc4.xml · nonDerivative · entry 2 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,725,733 Read SEC document |
| May 10, 2017 Filed May 11, 2017 10:50 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 10,000 | $6.94 | $69,400.00 |
DisclosureSEC source: 0001209191-17-031425 · doc4.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,723,133 Read SEC document |
| May 10, 2017 Filed Feb 5, 2019 21:26 UTC Amendment | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 10,000 | $6.99 | $69,900.00 |
DisclosureSEC source: 0001209191-19-007339 · doc4a.xml · nonDerivative · entry 5 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,657,404 F1 · date: The securities were erroneously reported as being purchased by the reporting person and owned directly on a Form 4 filed on May 11, 2017. The securities were purchased by Hsu Gamma Investment, L.P. and are owned indirectly by the reporting person. This Form 4 corrects the name and ownership of the securities. No other information has changed. F1 · kind: The securities were erroneously reported as being purchased by the reporting person and owned directly on a Form 4 filed on May 11, 2017. The securities were purchased by Hsu Gamma Investment, L.P. and are owned indirectly by the reporting person. This Form 4 corrects the name and ownership of the securities. No other information has changed. F2 · ownership.nature: The securities are owned directly by Hsu Gamma Investment, L.P. Dr. Hsiao is the general partner of Hsu Gamma Investment, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 10, 2017 Filed Feb 5, 2019 21:26 UTC Amendment | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 5,665 | $6.98 | $39,541.70 |
DisclosureSEC source: 0001209191-19-007339 · doc4a.xml · nonDerivative · entry 4 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,647,404 F1 · date: The securities were erroneously reported as being purchased by the reporting person and owned directly on a Form 4 filed on May 11, 2017. The securities were purchased by Hsu Gamma Investment, L.P. and are owned indirectly by the reporting person. This Form 4 corrects the name and ownership of the securities. No other information has changed. F1 · kind: The securities were erroneously reported as being purchased by the reporting person and owned directly on a Form 4 filed on May 11, 2017. The securities were purchased by Hsu Gamma Investment, L.P. and are owned indirectly by the reporting person. This Form 4 corrects the name and ownership of the securities. No other information has changed. F2 · ownership.nature: The securities are owned directly by Hsu Gamma Investment, L.P. Dr. Hsiao is the general partner of Hsu Gamma Investment, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 10, 2017 Filed Feb 5, 2019 21:26 UTC Amendment | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 11,735 | $6.97 | $81,792.95 |
DisclosureSEC source: 0001209191-19-007339 · doc4a.xml · nonDerivative · entry 3 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,641,739 F1 · date: The securities were erroneously reported as being purchased by the reporting person and owned directly on a Form 4 filed on May 11, 2017. The securities were purchased by Hsu Gamma Investment, L.P. and are owned indirectly by the reporting person. This Form 4 corrects the name and ownership of the securities. No other information has changed. F1 · kind: The securities were erroneously reported as being purchased by the reporting person and owned directly on a Form 4 filed on May 11, 2017. The securities were purchased by Hsu Gamma Investment, L.P. and are owned indirectly by the reporting person. This Form 4 corrects the name and ownership of the securities. No other information has changed. F2 · ownership.nature: The securities are owned directly by Hsu Gamma Investment, L.P. Dr. Hsiao is the general partner of Hsu Gamma Investment, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 10, 2017 Filed Feb 5, 2019 21:26 UTC Amendment | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 2,600 | $6.95 | $18,070.00 |
DisclosureSEC source: 0001209191-19-007339 · doc4a.xml · nonDerivative · entry 2 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,630,004 F1 · date: The securities were erroneously reported as being purchased by the reporting person and owned directly on a Form 4 filed on May 11, 2017. The securities were purchased by Hsu Gamma Investment, L.P. and are owned indirectly by the reporting person. This Form 4 corrects the name and ownership of the securities. No other information has changed. F1 · kind: The securities were erroneously reported as being purchased by the reporting person and owned directly on a Form 4 filed on May 11, 2017. The securities were purchased by Hsu Gamma Investment, L.P. and are owned indirectly by the reporting person. This Form 4 corrects the name and ownership of the securities. No other information has changed. F2 · ownership.nature: The securities are owned directly by Hsu Gamma Investment, L.P. Dr. Hsiao is the general partner of Hsu Gamma Investment, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 10, 2017 Filed Feb 5, 2019 21:26 UTC Amendment | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 10,000 | $6.94 | $69,400.00 |
DisclosureSEC source: 0001209191-19-007339 · doc4a.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,627,404 F1 · date: The securities were erroneously reported as being purchased by the reporting person and owned directly on a Form 4 filed on May 11, 2017. The securities were purchased by Hsu Gamma Investment, L.P. and are owned indirectly by the reporting person. This Form 4 corrects the name and ownership of the securities. No other information has changed. F1 · kind: The securities were erroneously reported as being purchased by the reporting person and owned directly on a Form 4 filed on May 11, 2017. The securities were purchased by Hsu Gamma Investment, L.P. and are owned indirectly by the reporting person. This Form 4 corrects the name and ownership of the securities. No other information has changed. F2 · ownership.nature: The securities are owned directly by Hsu Gamma Investment, L.P. Dr. Hsiao is the general partner of Hsu Gamma Investment, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 04, 2017 Filed Jan 5, 2017 16:11 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | Exercise / conversionStock Option (Right to Buy) · Derivative | 112,500 | $0.00 Strike: $7.61 | $0.00 |
DisclosureSEC source: 0001209191-17-001677 · doc4.xml · derivative · entry 6 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2020-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options were granted on March 18, 2013 and vest in four equal installments beginning on March 18, 2014. Read SEC document |
| January 04, 2017 Filed Jan 5, 2017 16:11 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | Exercise / conversionCommon Stock | 112,500 | $7.61 | $856,125.00 |
DisclosureSEC source: 0001209191-17-001677 · doc4.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,713,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2014 Filed Feb 5, 2019 21:31 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 10,000 | $7.96 | $79,600.00 |
DisclosureSEC source: 0001209191-19-007347 · doc4.xml · nonDerivative · entry 2 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,465,147 Read SEC document |
| July 30, 2012 Filed Feb 5, 2019 21:31 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 30,000 | $4.35 | $130,500.00 |
DisclosureSEC source: 0001209191-19-007347 · doc4.xml · nonDerivative · entry 4 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,727,404 F1 · ownership.nature: The securities are owned directly by Hsu Gamma Investment, L.P. Dr. Hsiao is the general partner of Hsu Gamma Investment, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 27, 2012 Filed Feb 5, 2019 21:31 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 20,000 | $4.30 | $86,000.00 |
DisclosureSEC source: 0001209191-19-007347 · doc4.xml · nonDerivative · entry 3 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,697,404 F1 · ownership.nature: The securities are owned directly by Hsu Gamma Investment, L.P. Dr. Hsiao is the general partner of Hsu Gamma Investment, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 21, 2011 Filed Feb 5, 2019 21:31 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GiftCommon Stock | 831,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-007347 · doc4.xml · nonDerivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,455,147 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.